BrightAccountsProduction v1.0.0 v1.0.0 2025-04-01 The company was not dormant during the period The company was trading for the entire period Unaudited Accounts The principal activity of the company is the preparation and retail of pharmaceutical and medicinal products. 29 June 2026 22 22 NI639414 2026-03-31 NI639414 2025-03-31 NI639414 2024-03-31 NI639414 2025-04-01 2026-03-31 NI639414 2024-04-01 2025-03-31 NI639414 uk-bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 NI639414 uk-curr:PoundSterling 2025-04-01 2026-03-31 NI639414 uk-bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 NI639414 uk-bus:FullAccounts 2025-04-01 2026-03-31 NI639414 uk-bus:Director1 2025-04-01 2026-03-31 NI639414 uk-bus:RegisteredOffice 2025-04-01 2026-03-31 NI639414 uk-bus:Agent1 2025-04-01 2026-03-31 NI639414 uk-core:ShareCapital 2026-03-31 NI639414 uk-core:ShareCapital 2025-03-31 NI639414 uk-core:RetainedEarningsAccumulatedLosses 2026-03-31 NI639414 uk-core:RetainedEarningsAccumulatedLosses 2025-03-31 NI639414 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2026-03-31 NI639414 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2025-03-31 NI639414 uk-bus:FRS102 2025-04-01 2026-03-31 NI639414 uk-core:LandBuildings 2025-04-01 2026-03-31 NI639414 uk-core:PlantMachinery 2025-04-01 2026-03-31 NI639414 uk-core:FurnitureFittingsToolsEquipment 2025-04-01 2026-03-31 NI639414 uk-core:CurrentFinancialInstruments 2026-03-31 NI639414 uk-core:CurrentFinancialInstruments 2025-03-31 NI639414 uk-core:CurrentFinancialInstruments 2026-03-31 NI639414 uk-core:CurrentFinancialInstruments 2025-03-31 NI639414 uk-core:WithinOneYear 2026-03-31 NI639414 uk-core:WithinOneYear 2025-03-31 NI639414 uk-core:EmployeeBenefits 2025-03-31 NI639414 uk-core:EmployeeBenefits 2025-04-01 2026-03-31 NI639414 uk-core:AcceleratedTaxDepreciationDeferredTax 2026-03-31 NI639414 uk-core:TaxLossesCarry-forwardsDeferredTax 2026-03-31 NI639414 uk-core:OtherDeferredTax 2026-03-31 NI639414 uk-core:RevaluationPropertyPlantEquipmentDeferredTax 2026-03-31 NI639414 uk-core:EmployeeBenefits 2026-03-31 NI639414 uk-core:ParentEntities 2025-04-01 2026-03-31 NI639414 2025-04-01 2026-03-31 NI639414 uk-bus:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 xbrli:pure iso4217:GBP xbrli:shares
Company Registration Number: NI639414
 
 
Camlough Pharmacy Ltd
 
Unaudited Financial Statements
 
for the financial year ended 31 March 2026
Camlough Pharmacy Ltd
DIRECTOR AND OTHER INFORMATION

 
Director Mr R Garvey
 
 
Company Registration Number NI639414
 
 
Registered Office 32a Main Street
Camlough
Co. Down
Northern Ireland
 
 
Business Address 32a Main Street
Camlough
Newry
Co. Down
BT35 7JG
United Kingdom
 
 
Accountants MG accountants
(Portadown)
25-27 Carleton Street
Portadown
Co. Armagh
BT62 3EP
Northern Ireland



Camlough Pharmacy Ltd
Company Registration Number: NI639414
BALANCE SHEET
as at 31 March 2026

2026 2025
Notes £ £
 
Fixed Assets
Tangible assets 4 26,109 53,441
───────── ─────────
 
Current Assets
Stocks 5 175,000 175,000
Debtors 6 204,559 516,481
Cash and cash equivalents 126,591 82,064
───────── ─────────
506,150 773,545
───────── ─────────
Creditors: amounts falling due within one year 7 (328,479) (298,707)
───────── ─────────
Net Current Assets 177,671 474,838
───────── ─────────
Total Assets less Current Liabilities 203,780 528,279
 
Provisions for liabilities 9 (9,071) (9,071)
───────── ─────────
Net Assets 194,709 519,208
═════════ ═════════
 
Capital and Reserves
Called up share capital 4 4
Retained earnings 194,705 519,204
───────── ─────────
Equity attributable to owners of the company 194,709 519,208
═════════ ═════════
 
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).
           
The company has taken advantage of the exemption under section 444 not to file the Profit and Loss Account and Director's Report.
           
For the financial year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.
           
The director confirms that the members have not required the company to obtain an audit of its financial statements for the financial year in question in accordance with section 476 of the Companies Act 2006.
           
The director acknowledges their responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit and loss for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
           
Approved by the Director and authorised for issue on 29 June 2026
           
           
________________________________          
Mr R Garvey          
Director          
           



Camlough Pharmacy Ltd
NOTES TO THE FINANCIAL STATEMENTS
for the financial year ended 31 March 2026

   
1. General Information
 
Camlough Pharmacy Ltd is a company limited by shares incorporated and registered in Northern Ireland. The registered number of the company is NI639414. The registered office of the company is 32a Main Street, Camlough, Co. Down, Northern Ireland. The principal activity of the company is the preparation and retail of pharmaceutical and medicinal products. The financial statements have been presented in Pound (£) which is also the functional currency of the company.
         
2. Summary of Significant Accounting Policies
 
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
 
Statement of compliance
The financial statements of the company for the financial year ended 31 March 2026 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.
 
Basis of preparation
The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.
 
Turnover
Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.
 
Tangible assets and depreciation
Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:
 
  Land and buildings freehold - 4% Straight line
  Plant and machinery - 15% Straight line
  Fixtures, fittings and equipment - 15% Straight line
 
The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.
 
Stocks
Stocks are valued at the lower of cost and net realisable value. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition.  Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.
 
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
 
Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
 
Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

 
Ordinary share capital
The ordinary share capital of the company is presented as equity.
       
3. Employees
 
The average monthly number of employees, including director, during the financial year was 22, (2025 - 22).
 
  2026 2025
  Number Number
 
Shop Staff 22 22
  ═════════ ═════════
           
4. Tangible assets
  Land and Plant and Fixtures, Total
  buildings machinery fittings and  
  freehold   equipment  
  £ £ £ £
Cost
At 1 April 2025 22,167 116,856 175,019 314,042
  ───────── ───────── ───────── ─────────
 
At 31 March 2026 22,167 116,856 175,019 314,042
  ───────── ───────── ───────── ─────────
Depreciation
At 1 April 2025 9,641 108,718 142,242 260,601
Charge for the financial year 887 2,755 23,690 27,332
  ───────── ───────── ───────── ─────────
At 31 March 2026 10,528 111,473 165,932 287,933
  ───────── ───────── ───────── ─────────
Net book value
At 31 March 2026 11,639 5,383 9,087 26,109
  ═════════ ═════════ ═════════ ═════════
At 31 March 2025 12,526 8,138 32,777 53,441
  ═════════ ═════════ ═════════ ═════════
       
5. Stocks 2026 2025
  £ £
 
Pharmaceutical goods and goods for resale 175,000 175,000
  ═════════ ═════════
 
The replacement cost of stock did not differ significantly from the figures shown.
       
6. Debtors 2026 2025
  £ £
 
Trade debtors 3,503 2,034
Amounts owed by group undertakings 50,000 362,515
Other debtors 127,074 129,687
Taxation  (Note 8) 16,596 14,859
Prepayments and accrued income 7,386 7,386
  ───────── ─────────
  204,559 516,481
  ═════════ ═════════
       
7. Creditors 2026 2025
Amounts falling due within one year £ £
 
Trade creditors 265,152 245,326
Taxation  (Note 8) 55,927 50,231
Other creditors 4,000 -
Accruals 3,400 3,150
  ───────── ─────────
  328,479 298,707
  ═════════ ═════════
       
8. Taxation 2026 2025
  £ £
 
Debtors:
VAT 16,596 14,859
  ═════════ ═════════
Creditors:
Corporation tax 51,030 45,306
PAYE / NI 4,897 4,925
  ───────── ─────────
  55,927 50,231
  ═════════ ═════════
         
9. Provisions for liabilities
 
The amounts provided for deferred taxation are analysed below:
 
  Capital Total Total
  allowances    
       
    2026 2025
  £ £ £
 
At financial year start 9,071 9,071 16,293
Charged to profit and loss - - (7,222)
  ───────── ───────── ─────────
At financial year end 9,071 9,071 9,071
  ═════════ ═════════ ═════════
       
10. Capital commitments
 
The company had no material capital commitments at the financial year-ended 31 March 2026.
           
11. Related party transactions
The company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure of transactions with group undertakings.
   
12. Parent company
 
The company regards Meigh Pharmacy Limited as its parent company.
 
   
13. Post-Balance Sheet Events
 
There have been no significant events affecting the company since the financial year-end.